Author:
McKean Norma,Chircop Charmaine
Abstract
We report a case of Guillain-Barré syndrome (GBS) occurring soon after the first dose of Vaxzevria (previously known as COVID-19 vaccine AstraZeneca). Thus far, there has been no evidence of an increased risk of GBS resulting from either COVID-19 infection nor from COVID-19 vaccines; however, individual cases and population cohorts should be scrutinised, in order to ensure the constant evaluation of such risks. It is as yet not possible to draw conclusions about any significant association between COVID-19 vaccination and GBS. A temporal correlation does not imply, and should not be deemed to signify, causality. However, it is important to remain vigilant, so that any potential increased risk is properly evaluated. The specific presentation of bifacial weakness as the initial symptom may be a characteristic feature of GBS in the context of recent COVID-19 vaccination.
Reference9 articles.
1. Covid-19 Dashboard. Available: https://deputyprimeminister.gov.mt/en/health-promotion/covid-19/Pages/covid-19-infographics.aspx [Accessed 6 Jul 2021].
2. Coronavirus (COVID-19) vaccinations. Available: https://ourworldindata.org/covid-vaccinations?country=MLT [Accessed 6 Jul 2021].
3. Guillain- Barré syndrome in the placebo and active arms of a COVID-19 vaccine clinical trial: temporal associations do not imply causality;Márquez Loza;Neurology,2021
4. Guillain-Barré syndrome variant occurring after SARS-CoV-2 vaccination;Allen;Ann Neurol,2021
5. Guillain-Barré syndrome following ChAdOx1-S/nCoV-19 vaccine;Maramattom;Ann Neurol,2021
Cited by
86 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献